DCI Research

Gynecologic oncologist Angeles Alvarez Secord, MD, MHS, weighs in on screening & symptoms in ovarian cancer. September is National Ovarian Cancer Awareness Month.

Komen NCTC hosts its first annual gala to support metastatic breast cancer research; a virtual event with speakers, auctions, and treats on Saturday, October 10, at 7 p.m.

A new approach to training computational models on biological processes provides insights into how and why cancer cells metastasize to certain areas of the vasculature.

Diagnosed with stage 4 ovarian cancer three years ago, Kathy Jennings was thrown a lifeline when she came to Duke Cancer Center.

A vaccine for HER2-positive breast cancers that is being tested in a clinical trial at DCI is part of an effective, two-drug strategy for enlisting the immune system to fight tumors.

Radiation oncologist Joseph Kamel Salama, MD, named to the 2020 class of ASTRO Fellows.

New optical sensing platform can detect genomic cancer biomarkers directly in patient tissues.

Research led by DCI member David Sherwood, PhD, may help pinpoint what might be going wrong in human diseases ranging from kidney disease to invasive cancer.

On-demand viewing of AACR Annual Meeting sessions is now available. Duke presenters included Hema Adhikari, PhD, and Daniel George, MD.

Duke Cancer Institute welcomes a new clinical investigator specializing in bladder cancer to its Genitourinary Oncology program.

In May, a phased-in process of reopening labs began, and by June 15 most labs were functioning at least on a partial basis.

On June 9, DCI and Susan G. Komen Triangle to Coast hosted "Navigating Survivorship,"a live patient forum on breast cancer and survivorship.

Cancer doesn't wait for COVID-19.

The Donald Lab, led by Bruce Donald, PhD, is designing proteins for a historically undruggable protein that’s implicated in difficult-to-treat cancers like pancreatic cancer.

Lyerly, Hartman spinout company Replicate Bioscience and Immunomic Therapeutics form collaboration to combat infectious diseases and cancers.

The Duke Cancer Institute Virtual Grand Rounds Series, came to a successful summer close with its final session on June 19.

Funding from the Elsa U. Pardee Foundation will allow investigator to study muscle regeneration and cancer.

Immunology expert Allan Kirk, MD, PhD, discusses what compels the immune system to respond to danger, and how our immune systems change over time.

Scott Soderling, PhD, has founded a Duke spinout company based on a technology developed in his lab that uses the genome-editing tool CRISPR.

 Yvonne Mowery, MD, PhD, was one of four young physician-scientists nationwide selected to receive the Damon Runyon Clinical Investigator Award.

Radiation oncologist Junzo Chino, MD, served as vice chair of the task force releasing recommendations for radiation therapy in nonmetastatic cervical cancer.

The authors, including corresponding author Madan Kwatra, MD, report that osimertinib inhibits the constitutive activity of EGFRv III tyrosine kinase with high potency.

Duke Cancer Institute will present more than 100 abstracts across multiple cancer types during the ASCO20 Virtual Scientific Program of the 2020 ASCO Annual Meeting.

Duke Cancer Institute's Michael Spiritos, MD, Meenal Kheterpal, MD, Momen Wahidi, MD, MBA, and Mustafa Bashir, MD, awarded 2020 DIHI Innovation Project Grants.

Duke Cancer Institute member and family physician Kevin Oeffinger, MD, has been named a Fellow of the American Society of Clinical Oncology (FASCO). 

Medical oncologist John Strickler, MD, and his patient Tom Vibert, a stage 4 colon cancer survivor, talk about the importance of biomarker testing.

Kyle Strickland, MD, PhD, received a Foundation for Women’s Cancer grant for research on endometrial cancer.

The research team found a signaling pathway within melanoma and other cancers that thwart the functioning of anti-PD-1 checkpoint inhibitors.

Duke University School of Medicine podcast "HeadScratchers" features Kelly Marcom, MD.

Christopher Kelsey, MD, associate professor in the Department of Radiation Oncology and DCI member, was awarded the 2020 Algernon Sydney Sullivan Award.

Nia Mitchell, MD, MPH, will presents: "Developing a Framework for Integrating Take Off Pounds Sensibly (TOPS) into Community Health Centers."

Kris Wood, PhD, and team, are investigating how to turn a tumor’s strength – its drug resistance – into a weakness. This research was published in Nature Genetics.

If mothers, sisters and daughters have a history of breast and ovarian cancers, a man's risk for prostate cancer is also significantly increased.

Graduate program rankings released today by U.S. News & World Report place the School of Nursing and School of Medicine among the top in the nation.

Yousuf Zafar, MD, MHS, FASCO, was honored to deliver the keynote for this year's ASCO Gastrointestinal Cancers Symposium.

Lifetime Achievement Award Winner Keith Sullivan, MD, and colleagues reflect on his career and passion.

Thomas A. D’Amico, MD, chair, NCCN Quality and Outcomes Cmte: "These 22 measures represent a feasible standard for documenting quality improvement in cancer care."

A new Bone Metastasis Clinic focuses exclusively on patients like Pam Kohl whose cancer has spread to their arms, legs or pelvis.
 

Duke and Leica formally established a Leica Microsystems Center of Excellence at the Light Microscopy Shared Resource.

Mentored-research training award boosts the next generation of Duke physician-scientists.

The Duke Department of Pathology/Duke Clinical Labs has established the Division of Artificial Intelligence and Computational Pathology.

Duke researchers are using a $200,000 grant from NC Biotech to “supercharge” vital medical information.

Duke University ranked eighth among the nation’s top medical schools and research institutions for funding from the NIH.

Research on immunotherapy in NSCLC by Scott Antonia, MD, PhD, selected by ASCO for inclusion in Clinical Cancer Advances 2020.

DCI researchers use the modified polio virus to spur natural immune attack against tumors in animal studies.

Dorothy Sipkins, MD, PhD, and P. Kelly Marcom, MD, are co-PIs on a Phase 1 clinical trial of a new drug for breast cancer patients whose disease has spread to the bone.

Lawrence A. David, PhD, and Anthony D. Sung, MD, named recipients of the Damon Runyon-Rachleff Innovation Award for project to personalize pre-biotic treatments for HCT patients.

This year's Annual Report spotlights the work of the new Duke Center for Brain and Spine Metastasis at DCI as well as a Duke-Durham stomach cancer prevention partnership. 

For Preston Robert Tisch Brain Tumor Center staff assistant Anne Beebe, the center's annual Angels Among Us 5K and Walk of Hope is deeply personal.

Medical oncologist Edwin P. Alyea, III, MD, formerly with Dana-Farber Cancer Institute, has been named chief medical officer (CMO) for Duke Cancer Institute.